アブストラクト
| Title | オピオイド鎮痛薬 - 強オピオイド |
|---|---|
| Subtitle | 特集 新ガイドラインでこう変わった! がん疼痛治療薬の新しい使い方 |
| Authors | 国分秀也 |
| Authors (kana) | |
| Organization | 東京薬科大学薬学部薬学実務実習教育センター |
| Journal | 月刊薬事 |
| Volume | 63 |
| Number | 1 |
| Page | 39-43 |
| Year/Month | 2021 / 1 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points] ●腎機能低下時, モルヒネ, オキシコドン, およびヒドロモルフォンは減量する. ●腎不全患者では, モルヒネの使用を避ける. ●肝機能低下時, すべての強オピオイドは減量する. ●高齢者では, 強オピオイドの投与で呼吸抑制が増加するため, 減量するなど慎重に投与する. ●代謝酵素およびトランスポーターを考慮し, 薬物相互作用を考える. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Duthey B, et al: Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. J pain Symptom Manage, 47:283-297, 2014
- 2) Osborne R, et al: The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther, 54:158-167, 1993
- 3) Durnin C, et al: Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc, 44:81-82, 2001
- 4) Perlman R, et al: Intradialytic clearance of opioids: methadone versus hydromorphone. Pain, 154:2794-2800, 2013
- 5) Ishida JH, et al: Opioid analgesics and adverse outcomes among hemodialysis patients. Clin J Am Soc Nephrol, 13:746-753, 2018
残りの13件を表示する
- 6) Durnin C, et al: Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc, 44:83-84, 2001
- 7) Kotb HI, et al: Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. Br J Anaesth, 94:95-99, 2005
- 8) Homma M, et al: Pharmacokinetic analysis, analgesic effects, and adverse effects of tapentadol in cancer patients with pain. Biol Pharm Bull, 43:1000-1006, 2020
- 9) Komatsu T, et al: Population pharmacokinetics of oxycodone in patients with cancer-related pain. J Pain Palliat Care Pharmacother, 26:220-225, 2012
- 10) Kokubun H, et al: Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. J Pain Palliat Care Pharmacother, 26:98-104, 2012
- 11) Kokubun H, et al: Population pharmacokinetics of methadone after oral administration in japanese patients with cancer-related pain. J Pain Palliat Care Pharmacother, 1:1-8, 2020
- 12) Holdsworth MT, et al: Transdermal fentanyl disposition in elderly subjects. Gerontology, 40:32-37, 1994
- 13) Liukas A, et al: Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther, 84:462-467, 2008
- 14) Baillie SP, et al: Age and the pharmacokinetics of morphine. Age Ageing, 18:258-262, 1989
- 15) Cepeda MS, et al: Side effects of opioids during short-term administration: effect of age,gender,and race. Clin Pharmacol Ther, 74:102-112, 2003
- 16) Huang AR, et al: Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging, 29:359-376, 2012
- 17) 山下和海,他:高齢者における末期癌患者の癌性疼痛への最大オピオイド使用量の検討.日本老年医学会雑誌, 44:345-350, 2007
- 18) Vigano A, et al: Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer, 83:1244-1250, 1998
